{'fraction_non_alphanumeric': 0.02996845425867508, 'fraction_numerical': 0.015772870662460567, 'mean_word_length': 6.470588235294118, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Administration of GAS914 in an orthotopic pig‐to‐baboon heart transplantation model

Abstract:  Background:  Long‐term survival of transgenic cardiac xenografts is currently limited by a form of humoral rejection named acute vascular rejection. Preformed and elicited cytotoxic antibodies against Galα(1,3)Gal terminating carbohydrate chains, known as the primary cause of hyperacute rejection, are crucial for this process. We investigated whether GAS914, a soluble, polymeric form of a Galα(1,3)Gal trisaccharide would sufficiently minimize xenograft rejection of hDAF‐transgenic pig hearts orthotopically transplanted into baboons.